Endoscopic retrograde cholangiopancreatography (ERCP) is a minimally invasive medical procedure that combines upper gastrointestinal endoscopy with fluoroscopic imaging to diagnose and treat disorders of the bile ducts, pancreatic duct, and gallbladder.[1] It allows physicians to visualize the biliary and pancreatic systems by injecting a contrast dye through a side-viewing endoscope inserted via the mouth into the duodenum, enabling real-time X-ray assessment of duct anatomy and pathology.[2]Originally introduced in the 1960s as a diagnostic tool, ERCP has largely transitioned to a therapeutic modality, with its diagnostic role supplanted by less invasive techniques like magnetic resonance cholangiopancreatography (MRCP) and endoscopic ultrasound (EUS).[3] Today, it is primarily employed to relieve biliary or pancreatic duct obstructions, remove gallstones, place stents to bypass blockages, perform biopsies, or drain fluid collections in conditions such as choledocholithiasis, cholangitis, malignant strictures, and chronic pancreatitis.[4] The procedure is typically performed in an outpatient setting under conscious sedation or general anesthesia by a trained gastroenterologist, lasting 30 minutes to two hours depending on complexity.[5]While ERCP is effective, with success rates exceeding 90% for many interventions, it carries risks including post-ERCP pancreatitis (affecting 3-10% of cases), infection, bleeding, and rare bowel perforation.[6] Patient preparation involves fasting for several hours beforehand and adjusting medications, particularly blood thinners, to minimize complications.[1] Advances in endoscopic technology, such as single-use duodenoscopes, continue to enhance safety and efficacy by reducing infection transmission risks.[7]
Overview
Definition and Purpose
Endoscopic retrograde cholangiopancreatography (ERCP) is a specialized endoscopic procedure that integrates endoscopy with fluoroscopic imaging to enable visualization and intervention within the biliary and pancreatic ductal systems. This technique allows clinicians to examine and treat conditions affecting the bile ducts, which transport bile from the liver to the small intestine, and the pancreatic ducts, which carry digestive enzymes from the pancreas. By providing direct access to these structures, ERCP facilitates both diagnostic assessment and therapeutic management in a single session.[2]The procedure targets the anatomy of the duodenum, where a side-viewing duodenoscope is advanced to the major papilla of Vaterโthe site where the common bile duct (CBD) and main pancreatic duct (PD) converge and empty into the gastrointestinal tract. Cannulation of the CBD and PD through the papilla enables the injection of contrast agents for radiographic opacification, direct duct visualization, tissue sampling via biopsy or brush cytology, and therapeutic actions such as stone removal, stricture dilation, or stent insertion to restore ductal patency. These capabilities make ERCP particularly valuable for addressing obstructive or inflammatory disorders in these systems.[1][3]Historically, ERCP emerged in the pre-1970s as a primarily diagnostic modality, but it has since transitioned to a predominantly therapeutic tool, with over 90% of procedures now focused on interventions rather than diagnosis alone. This shift reflects improvements in endoscopic equipment, the rise of non-invasive alternatives like magnetic resonance cholangiopancreatography for initial evaluation, and expanded therapeutic options for complex pancreatobiliary pathologies. ERCP requires sedation or general anesthesia to minimize discomfort and movement, and it is performed by specially trained gastroenterologists in a controlled clinical setting.[3][8][9]
Historical Development
The first successful endoscopic retrograde cholangiopancreatography (ERCP) was performed in 1968 by William S. McCune, Paul E. Shorb, and Herbert L. Moscovitz at George Washington University in the United States, achieving cannulation and retrograde opacification of the main pancreatic duct using a fiberoptic duodenoscope.[10] Independently in the same year, Itaru Oi and Takemoto in Japan conducted the inaugural endoscopic cholangiography with a side-viewing duodenoscope, marking parallel origins of the technique on both sides of the Pacific.[11] These pioneering efforts established ERCP as a diagnostic modality for visualizing the biliary and pancreatic ducts, leveraging advancements in flexible endoscopy from the mid-1960s.[12]By the early 1970s, ERCP began shifting toward therapeutic applications, driven by innovations in endoscopic accessories. The introduction of endoscopic sphincterotomy in 1974 by Kawai et al. in Japan allowed for the extraction of common bile duct stones without surgery.[13] Concurrently and independently, Classen and Demling in Germany reported the same technique, further enabling therapeutic interventions like stone removal and biliary decompression.[14] This milestone transformed ERCP from a primarily diagnostic tool into a hybrid procedure capable of addressing obstructive pathologies directly.[11]The 1980s and 1990s brought key technological refinements that expanded ERCP's scope and safety. Side-viewing duodenoscopes evolved with enhanced fiberoptic imaging and the transition to video endoscopy, improving papillary visualization and instrument control for complex cannulations.[11] Endoscopic papillary balloon dilation was introduced in 1983 by Staritz et al. as a sphincterotomy alternative for stone extraction, reducing cutting-related risks while facilitating dilation of the ampulla. Plastic stents emerged in 1979 for biliary drainage in malignant obstructions, providing temporary relief with straightforward placement via the endoscope.[15]In the 2000s, ERCP benefited from broader adoption of advanced therapeutics and standardized metrics. Self-expanding metal stents (SEMS) gained widespread use starting from their late-1980s origins, particularly for palliation of malignant strictures due to superior patency over plastic options.[16] Wire-guided cannulation, initially described by Siegel in 1987, became routine to enhance selective duct access and minimize post-procedure pancreatitis.[17] The American Society for Gastrointestinal Endoscopy (ASGE) formalized quality indicators, targeting over 85% success for selective biliary cannulation at the native papilla to ensure procedural efficacy.[18]The 2010s focused on standardization to optimize outcomes amid ERCP's therapeutic dominance. Guidelines recommended endoscopists maintain proficiency through a minimum of 100-200 procedures annually, with units performing at least 200 to support high-volume expertise.[19] Therapeutic procedures now constitute over 90% of all ERCPs, reflecting a decline in purely diagnostic uses due to noninvasive imaging alternatives.[20]In the 2020s, the adoption of single-use duodenoscopes, first authorized by the FDA in 2019 for marketing, has enhanced safety by minimizing infection transmission risks associated with reusable devices.[21]
Clinical Applications
Diagnostic Uses
Endoscopic retrograde cholangiopancreatography (ERCP) plays a crucial role in diagnosing pancreatobiliary disorders by enabling direct opacification of the biliary and pancreatic ducts with iodinated contrast, which highlights structural abnormalities such as choledocholithiasis, benign or malignant strictures, tumors, ductal leaks, and sphincter of Oddi dysfunction. This fluoroscopic visualization allows for precise identification of pathologies that may be obscured or indeterminate on non-invasive imaging modalities like ultrasound or magnetic resonance cholangiopancreatography (MRCP). Diagnostic ERCP is particularly indicated when prior imaging fails to clarify findings, such as unexplained common bile duct (CBD) dilation, or when there is a high suspicion for malignancy requiring tissue confirmation to guide management.[2][22]Specific diagnostic applications include the evaluation of cholangiocarcinoma, where ERCP facilitates targeted sampling of suspicious strictures in the extrahepatic or intrahepatic bile ducts to differentiate malignant from benign lesions. It is also employed for assessing ampullary adenomas, permitting visualization of intraductal extension and acquisition of cytological or histological samples to determine dysplasia or invasion. In chronic pancreatitis, ERCP delineates pancreatic duct irregularities, including main duct strictures, side-branch ectasia, and calculi, which support the Cambridge classification for staging disease severity when cross-sectional imaging is inconclusive. These indications prioritize ERCP over purely diagnostic alternatives when sampling or immediate therapeutic potential, such as sphincterotomy, is anticipated.[23]02782-9/fulltext)[24]Key diagnostic techniques during ERCP encompass brush cytology, where a cytological brush is advanced through the endoscope to abrade and collect cells from strictures, yielding sensitivities of 40-60% for malignancy when used alone; intraductal biopsy using forceps for more substantial tissue retrieval, which improves specificity to near 100%; and cholangioscopy via single-operator systems like SpyGlass for real-time direct visualization of mucosal lesions, enabling directed biopsies with reported diagnostic accuracies up to 88%. Combining these modalities enhances overall yield, particularly for indeterminate strictures. Procedural success, defined by selective duct cannulation, exceeds 90% in experienced centers, while the diagnostic yield for confirming malignancy in biliary strictures reaches 70-80% with multimodal sampling.[25]00659-3/fulltext)[26][27]
Therapeutic Uses
Endoscopic retrograde cholangiopancreatography (ERCP) serves as a primary interventional modality for treating disorders of the biliary and pancreatic ducts, enabling direct access for therapies that alleviate obstruction, remove calculi, and facilitate drainage.[28] Core therapeutic actions include endoscopic sphincterotomy (EST) to incise the ampulla of Vater for improved access, balloon dilation to widen strictures, and mechanical lithotripsy to fragment large stones for extraction.[29]EST achieves successful stone removal in over 90% of cases, while large balloon dilation following limited EST yields complete duct clearance in 94-100% of procedures for difficult stones.[30] Mechanical lithotripsy, often combined with EST, reports a 90% success rate in clearing common bile duct stones larger than 15 mm.[31]Specific applications encompass extraction of common bile duct (CBD) stones in choledocholithiasis, with overall success rates exceeding 95% through techniques like basket retrieval post-EST.[32] For malignant biliary obstruction, such as from pancreatic head tumors, ERCP facilitates stenting to restore bile flow; plastic stents provide patency of approximately 3 months, whereas self-expanding metal stents extend this to 6-12 months, reducing reintervention needs.[33] In pancreatic duct disorders, including recurrent pancreatitis due to strictures or stones, ERCP enables drainage via stenting, with prolonged placement (6-12 months) promoting stricture remodeling and symptom relief in most cases.[34] Post-cholecystectomy bile leaks are effectively managed with ERCP-placed stents or sphincterotomy, achieving high closure rates without dependency on procedure timing.[35]Advanced therapies during ERCP include pancreatic sphincterotomy for selective pancreatic duct access in chronic pancreatitis, the rendezvous techniqueโcombining percutaneous or EUS-guided wire placement with endoscopic captureโfor difficult cannulation scenarios, and photodynamic therapy (PDT) for unresectable cholangiocarcinoma, where laser activation of photosensitizers targets tumor tissue to prolong survival beyond stenting alone.[36] PDT integrated with ERCP improves median survival and quality of life compared to biliary stenting in advanced cholangiocarcinoma.30166-3/pdf)Patient selection for therapeutic ERCP prioritizes individuals with symptomatic choledocholithiasis confirmed by elevated liver enzymes and imaging, obstructive jaundice from tumors causing cholangitis, and post-cholecystectomy bile leaks presenting with abdominal pain or biloma. Outcomes demonstrate symptom resolution in 80-95% of benign conditions like choledocholithiasis following stone extraction, with overall technical success nearing 100% for uncomplicated cases.[32] For malignant obstruction, palliation achieves clinical success in 70-95% initially, though long-term patency varies by stent type and tumor biology.[37]
Preparation and Contraindications
Patient Preparation
Patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) must adhere to fasting requirements to reduce the risk of aspiration during sedation, typically remaining nil per os (NPO) for solids for 6-8 hours and clear liquids for 2-4 hours prior to the procedure.[38]Laboratory evaluations are essential for assessing procedural safety, including a complete blood count (CBC) to evaluate for anemia or infection, liver function tests (LFTs) to assess biliary obstruction, and coagulation profile with prothrombin time (PT) and international normalized ratio (INR) ideally less than 1.5 for procedures involving potential bleeding such as sphincterotomy.[2] Prophylactic antibiotics, such as ciprofloxacin or ampicillin-sulbactam, are administered to patients with suspected or confirmed cholangitis, immunocompromised states, or anticipated incomplete biliary drainage. Patients with a history of allergy to iodinated contrast should be evaluated for premedication or alternative approaches.[39]Medication adjustments focus on minimizing bleeding and thromboembolic risks; oral anticoagulants like warfarin are typically held for 5 days pre-procedure with bridging low-molecular-weight heparin for high-thromboembolic-risk patients, while direct oral anticoagulants (DOACs) are discontinued 1-2 days prior based on renal function.[40] Low-dose aspirin may be continued, but dual antiplatelet therapy requires individualized assessment, often holding the P2Y12 inhibitor 5-7 days pre-procedure if high bleeding risk.[41]Informed consent involves a detailed discussion of procedural risks, including post-ERCP pancreatitis occurring in 5-10% of cases, potential need for sedation (moderate conscious sedation with midazolam and fentanyl or general anesthesia), and alternatives to the procedure.[42]Special considerations for high-risk patients include administration of prophylactic rectal indomethacin (100 mg) immediately before or after ERCP to reduce the incidence of post-ERCP pancreatitis, particularly in those with factors such as prior pancreatitis, small bile duct diameter, or difficult cannulation.[43] Additionally, aggressive intravenous hydration with lactated Ringer's solution (at least 250 mL/hour during and after the procedure) is recommended to further mitigate pancreatitis risk in select cases.[43]
Contraindications and Precautions
Endoscopic retrograde cholangiopancreatography (ERCP) has few absolute contraindications, primarily those conditions where proceeding would pose an unacceptably high risk of immediate harm or violate patient autonomy. These include patient refusal or lack of informed consent outside of life-threatening emergencies, as consent is essential for non-emergent procedures.[44] Unstable cardiopulmonary status, such as severe respiratory failure or hemodynamic instability, is another absolute contraindication due to the inability to safely administer sedation and manage potential procedural stress.[23] Similarly, recent myocardial infarction within the past month contraindicates ERCP, as the procedure's demands could exacerbate cardiac compromise.[45] Uncorrectable coagulopathy, defined as platelet count below 50,000/ฮผL or international normalized ratio (INR) greater than 1.5 despite attempts at correction, is considered absolute because it significantly elevates bleeding risks during ductal manipulation or sphincterotomy.[44]Relative contraindications involve scenarios where ERCP may be feasible but requires careful risk-benefit evaluation and potential modifications. Acute severe pancreatitis is a relative contraindication, as the inflamed pancreatic duct increases the likelihood of exacerbating the condition, though ERCP may be pursued if cholangitis or obstruction necessitates urgent intervention.[23]Pregnancy represents a relative contraindication owing to fetal radiation exposure from fluoroscopy, typically limited to under 50 mGy with precautions, but therapeutic ERCP is often justified for maternal indications like choledocholithiasis when alternatives are unsuitable.[46] Altered gastrointestinal anatomy, such as post-Billroth II gastrectomy, poses technical challenges that may necessitate advanced endoscopes or techniques, rendering it relative rather than prohibitive.[47] An uncooperative patient is also relative, as moderate sedation or general anesthesia might mitigate this, but severe agitation could preclude safe cannulation.[45]Precautions are particularly relevant for high-risk patient groups to minimize adverse events. Elderly patients warrant heightened vigilance for sedation-related complications, including respiratory depression, due to age-related declines in organ function and polypharmacy interactions.[48] Obesity presents access difficulties during endoscopy and positioning, potentially prolonging procedure time and increasing perforation risk, so multidisciplinary planning with anesthesiology is advised.[49] Individuals with a history of prior failed ERCP should undergo evaluation for anatomical or technical barriers, often favoring alternatives like endoscopic ultrasound-guided approaches to avoid repeated failures.[50]Risk stratification tools aid in identifying patients prone to complications like post-ERCP pancreatitis (PEP), which affects approximately 15% of high-risk individuals compared to 8% overall. The American Society for Gastrointestinal Endoscopy (ASGE) guidelines recommend assessing factors such as young age, female sex, sphincter of Oddi dysfunction, and difficult biliary cannulation to classify risk; for high-risk cases, prophylactic measures like rectal nonsteroidal anti-inflammatory drugs and aggressive hydration are standard.[43] Procedural modifications, including short-wire systems for challenging cannulation, can reduce PEP incidence by limiting pancreatic duct trauma.[51]Ethical considerations emphasize thorough informed consent discussing procedure-specific risks and alternatives, ensuring decisions align with patient values and clinical necessity. In cases approaching contraindications, clinicians must weigh benefits against harms, prioritizing non-invasive options like magnetic resonance cholangiopancreatography when diagnostic yield is sufficient, to uphold principles of beneficence and non-maleficence.[52]
Procedure
Equipment and Technique
Endoscopic retrograde cholangiopancreatography (ERCP) requires specialized equipment to facilitate visualization, access, and intervention within the biliary and pancreatic ducts. The primary instrument is a side-viewing duodenoscope, such as a therapeutic model with an elevator mechanism for precise control of accessories, allowing oblique views of the duodenum and papilla; duodenoscopes may be reusable or disposable single-use models to reduce infection risks.[53] A fluoroscopy unit is essential for real-time radiographic imaging during duct navigation and contrast administration. Water-soluble iodinated contrast media, like iohexol, is used for opacification of the ducts. Guidewires, typically 0.035-inch hydrophilic types, enable selective duct access and serve as rails for subsequent devices. Additional accessories include sphincterotomes for papillary incision, extraction balloons for stone removal, and retrieval baskets for tissue or calculi capture.[2][54][55]The procedure begins with intravenous sedation, commonly using midazolam and fentanyl, to ensure patient comfort while maintaining airway control. The side-viewing duodenoscope is advanced through the mouth, esophagus, stomach, and into the second portion of the duodenum, where it is positioned to face the major papilla. The papilla is identified and assessed for abnormalities, followed by selective cannulation of the desired ductโpreferentially the common bile ductโusing wire-guided techniques, which achieve success rates exceeding 90%. Once access is secured, contrast medium is injected under fluoroscopic guidance to map the ductal anatomy, revealing strictures, stones, or leaks.[2][56][57]In cases of difficult cannulation, occurring in approximately 10% of procedures, variations such as precut sphincterotomy may be employed, involving controlled incision of the papillary roof with a sphincterotome to facilitate access. The double-guidewire technique offers an alternative, where a wire is placed in the pancreatic duct to stabilize the papilla, allowing a second wire to target the biliary orifice more effectively. Therapeutic maneuvers, such as stent placement or stone extraction, can be integrated once cannulation is achieved.[55][58]ERCP is typically performed in an endoscopy suite equipped with radiology support, lasting 30 to 90 minutes depending on complexity. Quality benchmarks include selective cannulation within 5 minutes and overall procedural success rates greater than 85% for therapeutic objectives.[2][59]
Post-Procedure Care
Following the completion of an endoscopic retrograde cholangiopancreatography (ERCP), patients are transferred to the post-anesthesia care unit (PACU) for close monitoring, typically lasting 1 to 4 hours, to allow recovery from sedation. During this period, vital signs such as blood pressure, heart rate, oxygen saturation, and respiratory status are regularly assessed, alongside pain evaluation using standardized scales to ensure patient comfort and detect any immediate issues. To prevent post-ERCP pancreatitis (PEP), rectal administration of 100 mg indomethacin or diclofenac is recommended immediately post-procedure for all patients, as it reduces PEP risk without significantly increasing bleeding even after sphincterotomy. Aggressive intravenous hydration with lactated Ringer's solution (e.g., 250-500 mL/h for 8 hours in high-risk cases) is also advised. Laboratory tests, including serum amylase levels checked 2 to 6 hours post-procedure, help evaluate the risk of post-ERCP pancreatitis by identifying elevations that may warrant further observation.[38][60][61][43]Dietary management begins with the patient remaining nil per os (NPO) immediately after the procedure to minimize nausea and aspiration risk. Progression to clear liquids is initiated once nausea subsides and the patient is alert, with advancement to a regular diet encouraged unless complications like pancreatitis are suspected; for those at moderate to high risk of post-ERCP pancreatitis, a low-fat diet is advised for at least 48 hours to reduce pancreatic stimulation. Intravenous fluids are administered during recovery to maintain hydration, particularly in cases involving aggressive periprocedural strategies.[1][62][63]Pain control focuses on mild to moderate discomfort from gas distension or procedural manipulation, managed with intravenous or oral analgesics such as opioids or acetaminophen. Antiemetics like ondansetron are routinely provided to alleviate bloating, nausea, or vomiting, which are common transient symptoms.[43][38]Discharge decisions are guided by criteria ensuring patient safety, including stable vital signs, ability to tolerate oral intake without vomiting, absence of fever, significant pain, or bleeding, and full recovery from sedation. Low-risk diagnostic procedures often allow same-day discharge, typically after 1 to 2 hours of observation, accompanied by an adult escort; therapeutic ERCP or high-risk cases, such as those with pancreatic duct manipulation, may necessitate overnight hospitalization for extended monitoring. Serum amylase less than 1.5 times the upper limit of normal and lipase less than 4 times the upper limit further support early discharge in appropriate candidates. Patients are educated on early signs of complications, such as worsening abdominal pain or fever, to seek immediate care.[61][38][60]Follow-up care includes a clinic visit 1 to 2 weeks post-procedure to review pathology results if biopsies were taken, assess symptom resolution, and evaluate stent patency through clinical exam or imaging such as ultrasound or CT if a biliary or pancreatic stent was placed. Additional appointments may be scheduled earlier for urgent cases or extended for ongoing stent management.[64][65]
Risks and Complications
Common Risks
The overall adverse event rate associated with endoscopic retrograde cholangiopancreatography (ERCP) ranges from 6% to 10%, with therapeutic procedures carrying a higher risk of 10% to 15%.[66][67]Post-ERCP pancreatitis (PEP) represents the most frequent complication, with an incidence of 3% to 10%.[68][69] Risk factors for developing PEP include younger patient age, female sex, suspected sphincter of Oddi dysfunction, prior history of PEP, and difficult cannulation of the papilla.[70][71] In high-risk cohorts, PEP occurs in up to 14.7% of cases, though approximately 75% to 80% of episodes are classified as mild, resolving with supportive care within a few days.[72]Sedation-related adverse events are common during ERCP, including hypoxemia (oxygen saturation below 90%) in 5% to 20% of procedures and hypotension (systolic blood pressure below 90 mmHg) in up to 18%.[73] These events are typically transient and can be mitigated through continuous monitoring of vital signs and oxygen supplementation.[73]Additional frequent, lower-severity issues include post-procedure bloating and abdominal discomfort, affecting 20% to 30% of patients due to insufflation of air or carbon dioxide during the procedure, and transient fever, often resolving without intervention.[74] Minor bleeding following sphincterotomy occurs in less than 5% of cases, usually self-limited and managed conservatively.[75][74]The risk of infection, particularly cholangitis from incomplete biliary drainage, stands at 1% to 2%, with elevated rates in patients with obstructed ducts or those undergoing stent placement for malignant strictures.[76][74]
Serious complications of endoscopic retrograde cholangiopancreatography (ERCP), though infrequent, can be life-threatening and require prompt recognition and intervention. These include perforation, severe bleeding, severe post-ERCP pancreatitis (PEP), sepsis or cholangitis, and procedure-related mortality. Management strategies emphasize early detection through vigilant post-procedure monitoring, such as serial imaging and clinical assessment, alongside tailored therapeutic approaches to minimize morbidity.[74]Perforation occurs in approximately 0.5-1% of ERCP procedures and is classified by location, including ampullary, duodenal, or ductal types. Ampullary perforations often result from sphincterotomy, while ductal perforations may arise from guidewire trauma; retroperitoneal duodenal perforations (Stapfer type II) are the most common. Management involves conservative approaches for contained perforations, including nil per os (NPO) status, antibiotics, and nasogastric suction, but endoscopic closure with clips or stents is preferred for accessible defects. Surgical intervention is reserved for free intraperitoneal perforations or failure of conservative/endoscopic measures, with success rates exceeding 80% for non-operative management in stable patients.[77][78][79]Severe bleeding, with an incidence of 0.7-2% primarily following endoscopic sphincterotomy (EST), can lead to hemodynamic instability and is more common in patients with coagulopathy or large incisions. Initial control is achieved endoscopically using hemoclips, epinephrine injection (1:10,000 dilution), or thermal coagulation, achieving hemostasis in over 90% of cases. Refractory bleeding may necessitate angiography with embolization or, rarely, surgery; transfusion requirements average 2-4 units in severe cases. Prevention includes pre-procedure correction of coagulopathy and judicious EST technique.[74][80]Severe post-ERCP pancreatitis (PEP) affects 0.5-1% of patients, often requiring intensive care unit admission due to systemic inflammatory response, organ failure, or necrosis. It is graded severe by Atlanta criteria, with prolonged hospitalization (>4 days) and interventions like percutaneous drainage. Treatment centers on aggressive intravenous hydration (250-500 mL/hour lactated Ringer's solution initially), pain management, and nutritional support; endoscopic or percutaneous drainage is indicated for infected necrosis or disconnected duct syndrome. Prophylactic measures, such as rectal indomethacin and pancreatic duct stenting, reduce severity in high-risk cases.[81][74]Sepsis or cholangitis complicates 0.5-1.5% of ERCPs, typically from incomplete biliary drainage or contaminated stents leading to bacteremia. Risk is heightened in obstructed systems with pus. Management includes broad-spectrum antibiotics (e.g., piperacillin-tazobactam) covering enteric pathogens, urgent biliary decompression via repeat ERCP or percutaneous transhepatic cholangiography, and source control; mortality drops below 5% with timely intervention within 24 hours. Prophylactic antibiotics are recommended for high-risk therapeutic ERCPs.[74][79][82]Overall mortality from ERCP is less than 0.5%, predominantly linked to comorbidities like advanced age or cardiopulmonary disease rather than the procedure itself. High operator volume (>100 ERCPs per year) reduces complication-related mortality by up to 50% through expertise in risk stratification and technique. Multidisciplinary care in high-volume centers further improves outcomes by facilitating rapid escalation for complications.[83]
Alternatives and Advances
Alternative Procedures
Magnetic resonance cholangiopancreatography (MRCP) serves as a non-invasive alternative for diagnostic evaluation of biliary and pancreatic ducts, particularly in detecting choledocholithiasis and strictures without the need for endoscopy or radiation exposure. MRCP demonstrates high sensitivity (85-95%) and specificity (85-100%) for identifying common bile duct stones greater than 5 mm, making it preferable for initial assessment in patients with suspected biliary obstruction where therapeutic intervention is not immediately required.[84][85] However, MRCP is limited to imaging and cannot facilitate interventions like stone removal or stent placement.Endoscopic ultrasound (EUS) provides a minimally invasive option for detailed biliary and pancreatic evaluation, including duct visualization, tumor staging, and fine-needle aspiration (FNA) for tissue sampling. EUS excels in detecting small pancreatic tumors (<3 cm), ampullary neoplasms, and bile duct stones (<4 mm) with superior accuracy compared to other imaging modalities, and it is often preferred when ERCP is contraindicated due to altered anatomy.[86] The complication rate for EUS-guided FNA remains low, typically under 2%, with rare instances of pancreatitis, infection, or perforation.[87]For cases where ERCP fails, particularly due to inaccessible papillae, percutaneous transhepatic cholangiography (PTC) offers an invasive alternative for biliary access and drainage. PTC achieves technical success rates exceeding 95% in dilated bile ducts, enabling external or internal drainage, though it carries complication rates of 10-20%, including cholangitis, hemorrhage, and sepsis.[88][89] It is typically reserved for malignant obstructions or when endoscopic approaches are not feasible.EUS-guided biliary drainage (EUS-BD) has emerged as a salvage procedure following unsuccessful ERCP, providing transgastric or transduodenal access to the biliary system. Clinical success rates for EUS-BD reach 90-94%, comparable to ERCP, but with lower rates of adverse events such as post-procedure pancreatitis (6% vs. higher in repeat ERCP).[90][91] This approach is favored in patients with altered anatomy or prior failed cannulation to avoid repeated endoscopic risks.Surgical interventions remain options for complex cases, such as laparoscopic common bile duct exploration (LCBDE) with choledochotomy for choledocholithiasis refractory to endoscopic management. LCBDE yields stone clearance rates of 94% or higher, with outcomes comparable to ERCP in terms of morbidity, though it may reduce hospital stays and costs in select patients.[92] For pancreatic head tumors causing biliary obstruction, the Whipple procedure (pancreaticoduodenectomy) is indicated, achieving curative intent but with morbidity rates of 30-40% and mortality under 2%.[93][94] These surgical alternatives are preferred when comprehensive resection is needed alongside biliary relief.
Recent Advances
Recent advances in endoscopic retrograde cholangiopancreatography (ERCP) have focused on enhancing safety, efficacy, and accessibility through innovative devices and techniques, particularly addressing infection risks and procedural challenges post-2020.[95]Disposable duodenoscopes, such as the Ambu aScope, have emerged as a key innovation to mitigate infection transmission, spurred by post-2015 carbapenem-resistant Enterobacteriaceae (CRE) outbreaks associated with reusable endoscopes. These single-use devices eliminate reprocessing-related contamination risks, with studies demonstrating their feasibility in ERCP procedures and comparable performance to reusable models in visualization and maneuverability. Adoption has increased, with multicenter trials from 2020 to 2023 reporting successful completion rates exceeding 90% and zero device-related infections in evaluated cohorts.[96][97][95]Digital cholangioscopes have improved intraductal visualization during ERCP, enabling high-definition imaging and targeted interventions for biliary pathologies. These disposable or semi-disposable systems offer wider fields of view and enhanced resolution compared to fiberoptic predecessors, facilitating direct assessment of strictures and stones with diagnostic accuracy improved by meta-analyses showing sensitivity rates above 85% for indeterminate lesions. Recent guidelines from 2025 recommend their use in undefined biliary strictures at index ERCP to optimize biopsy yields and reduce repeat procedures.[98][99][100]Technique enhancements include rapid on-site evaluation (ROSE) for ERCP-guided biopsies, which has boosted diagnostic yield in biliary strictures. ROSE allows immediate cytologic assessment, achieving accuracy rates over 90% in 2023-2025 studies by minimizing inadequate samples and guiding additional sampling intra-procedurally. Additionally, enteroscopy-assisted ERCP has advanced management in patients with altered anatomy, such as Roux-en-Y gastric bypass, with success rates around 80-85% using single- or double-balloon enteroscopes for deep intubation and cannulation.[101][102][103]Integration of ERCP with endoscopic ultrasound (EUS) has refined biliary drainage options, notably through EUS-guided hepaticogastrostomy (HGS) as a primary alternative to percutaneous transhepatic biliary drainage (PTBD). 2024 comparative data indicate HGS yields lower adverse event rates (13% versus 58% for PTBD), shorter procedure times, and improved patient satisfaction in cases of failed conventional ERCP.[104][105]Artificial intelligence (AI) applications in fluoroscopy have enhanced wire guidance during ERCP, dynamically optimizing imaging to reduce radiation exposure by 20-30% through automated collimation and dose modulation. Lumen-apposing metal stents (LAMS) have similarly advanced drainage strategies, particularly in EUS-guided procedures, offering bidirectional patency and lower reintervention rates compared to traditional plastic stents in 2020-2025 trials.[106][107]00611-1/fulltext)Quality improvement efforts in 2024-2025 guidelines emphasize endoscopist volume thresholds of at least 150 ERCPs per year to minimize complications, alongside standardized post-ERCP pancreatitis (PEP) prophylaxis using rectal indomethacin combined with intravenous saline hydration, which reduces PEP incidence by approximately 30% in high-risk patients.[108][109]